As Amgen's trio of Horizon drugs disappoints, execs urge analysts to give them more time
While Amgen’s legacy products are thriving, those gained from the company’s $27.8 billion buyout of Horizon Therapeutics in 2023 are struggling, especially blockbuster eye disease treatment Tepezza, which saw a 17% sequential decline in the first quarter.
While Amgen’s legacy products are thriving, those gained from the company’s $27.8 billion buyout of Horizon Therapeutics in 2023 are struggling, especially blockbuster eye disease treatment Tepezza, which saw a 17% sequential decline in the first quarter.
